HK1056878A1 - Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1. - Google Patents
Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1.Info
- Publication number
- HK1056878A1 HK1056878A1 HK03109254A HK03109254A HK1056878A1 HK 1056878 A1 HK1056878 A1 HK 1056878A1 HK 03109254 A HK03109254 A HK 03109254A HK 03109254 A HK03109254 A HK 03109254A HK 1056878 A1 HK1056878 A1 HK 1056878A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- inhibitors
- beta
- dehydrogenase type
- steroid dehydrogenase
- hydroxy steroid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/84—Naphthothiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0001899A SE0001899D0 (sv) | 2000-05-22 | 2000-05-22 | New compounds |
PCT/SE2001/001157 WO2001090094A1 (en) | 2000-05-22 | 2001-05-22 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1056878A1 true HK1056878A1 (en) | 2004-03-05 |
Family
ID=20279781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK03109254A HK1056878A1 (en) | 2000-05-22 | 2003-12-19 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1. |
Country Status (24)
Country | Link |
---|---|
US (7) | US7618961B2 (xx) |
EP (4) | EP1283833A1 (xx) |
JP (4) | JP2003534339A (xx) |
KR (4) | KR20030016272A (xx) |
CN (4) | CN1188403C (xx) |
AR (1) | AR033534A1 (xx) |
AT (2) | ATE443055T1 (xx) |
AU (6) | AU2001262830A1 (xx) |
BR (1) | BR0111099A (xx) |
CA (4) | CA2408783A1 (xx) |
DE (3) | DE60143293D1 (xx) |
EA (1) | EA005274B1 (xx) |
ES (1) | ES2333846T3 (xx) |
HK (1) | HK1056878A1 (xx) |
HU (1) | HUP0302435A3 (xx) |
IL (4) | IL152669A0 (xx) |
MX (1) | MXPA02011632A (xx) |
NO (4) | NO20025588L (xx) |
NZ (4) | NZ522506A (xx) |
PE (1) | PE20020100A1 (xx) |
PL (1) | PL360137A1 (xx) |
SE (1) | SE0001899D0 (xx) |
WO (5) | WO2001090093A1 (xx) |
ZA (4) | ZA200209360B (xx) |
Families Citing this family (185)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0001899D0 (sv) | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
AU2001276378A1 (en) * | 2000-07-05 | 2002-01-14 | Bayer Aktiengesellschaft | Regulation of human 11 beta-hydroxysteroid dehydrogenase 1-like enzyme |
GB0107383D0 (en) * | 2001-03-23 | 2001-05-16 | Univ Edinburgh | Lipid profile modulation |
CA2466491A1 (en) * | 2001-11-22 | 2003-05-30 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
EA200400707A1 (ru) * | 2001-11-22 | 2004-10-28 | Биовитрум Аб | Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1 |
AU2007205749B2 (en) * | 2001-11-22 | 2009-04-23 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
US20030130279A1 (en) * | 2001-11-22 | 2003-07-10 | Guido Kurz | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
US7074788B2 (en) * | 2001-11-22 | 2006-07-11 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
CA2466490C (en) | 2001-11-22 | 2009-12-29 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
WO2003061655A1 (en) | 2002-01-16 | 2003-07-31 | University Of Virginia Patent Foundation | 2-aminothiazole allosteric enhancers of a1 adenosine receptors |
JP4368683B2 (ja) | 2002-02-01 | 2009-11-18 | メルク エンド カムパニー インコーポレーテッド | 糖尿病、肥満症および脂質代謝異常の治療に有用な11−ベータ−ヒドロキシステロイドデヒドロゲナーゼ1阻害剤 |
US7338969B2 (en) * | 2002-03-08 | 2008-03-04 | Quonova, Llc | Modulation of pathogenicity |
ATE450520T1 (de) * | 2002-03-29 | 2009-12-15 | Schering Corp | Stereoselektive alkylierung von chirale 2-methyl- 4-geschützte piperazinen |
SE0201194D0 (sv) * | 2002-04-19 | 2002-04-19 | Astrazeneca Ab | New compounds |
US20030198965A1 (en) | 2002-04-19 | 2003-10-23 | Isis Pharmaceuticals Inc. | Antisense modulation of hydroxysteroid 11-beta dehydrogenase 1 expression |
AR040241A1 (es) | 2002-06-10 | 2005-03-23 | Merck & Co Inc | Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia |
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
AU2003275195A1 (en) * | 2002-09-18 | 2004-04-08 | Hartmut M. Hanauske-Abel | INHIBITORS OF 11Beta-HYDROXYSTEROID DEHYDROGENASE AND USES THEREFOR |
JP2006506451A (ja) * | 2002-10-11 | 2006-02-23 | アストラゼネカ アクチボラグ | 1,4−ジ置換ピペリジン誘導体および11−βHSD1阻害薬としてのそれらの使用 |
GB0224830D0 (en) | 2002-10-24 | 2002-12-04 | Sterix Ltd | Compound |
MXPA05004434A (es) * | 2002-10-24 | 2005-07-26 | Sterix Ltd | Inhibidores de 11-beta-hidroxi esteroide deshidrogenasa tipo 1 y tipo 2. |
US20060058315A1 (en) * | 2002-11-07 | 2006-03-16 | Astrazeneca Ab | 2-Oxo-ethanesulfonamide derivates |
PE20040693A1 (es) * | 2002-11-14 | 2004-11-23 | Novartis Ag | N-sulfonilaminotiazol como mediadores de la sulfatasa de esteroides |
GB0226602D0 (en) * | 2002-11-14 | 2002-12-24 | Novartis Ag | Organic compounds |
JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
WO2004056744A1 (en) * | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
FR2849598B1 (fr) | 2003-01-07 | 2006-09-22 | Merck Sante Sas | Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans |
FR2849599B1 (fr) * | 2003-01-07 | 2006-12-29 | Merck Sante Sas | Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete |
TW200503994A (en) * | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
WO2004089470A2 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | New amide derivatives and pharmaceutical use thereof |
DE10314610A1 (de) | 2003-04-01 | 2004-11-04 | Aventis Pharma Deutschland Gmbh | Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung |
US7501405B2 (en) | 2003-04-11 | 2009-03-10 | High Point Pharmaceuticals, Llc | Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders |
WO2004089380A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Pharmaceutical use of fused 1,2,4-triazoles |
EP1785424A3 (en) * | 2003-04-11 | 2009-12-23 | High Point Pharmaceuticals, LLC | Fused 1,2,4-triazoles and pharmaceutical uses thereof |
US7700583B2 (en) | 2003-04-11 | 2010-04-20 | High Point Pharmaceuticals, Llc | 11β-hydroxysteroid dehydrogenase type 1 active compounds |
CA2525945A1 (en) * | 2003-05-21 | 2004-12-02 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i |
US7173030B2 (en) | 2003-05-21 | 2007-02-06 | Biovitrum Ab | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 |
JP4499106B2 (ja) | 2003-05-29 | 2010-07-07 | メルク・シャープ・エンド・ドーム・コーポレイション | 11−ベータ−水酸化ステロイド脱水素酵素−1の阻害剤としてのトリアゾール誘導体 |
SE0301884D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use III |
SE0301882D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use I |
WO2004113310A1 (en) * | 2003-06-25 | 2004-12-29 | Biovitrum Ab | Use of an inhibitor of 11-b-hydroxysteroid dehydrogenase type 1 compounds for promoting wound healing |
SE0301885D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use IV |
SE0301883D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use II |
CA2551037A1 (en) | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivative |
GB0324792D0 (en) | 2003-10-23 | 2003-11-26 | Sterix Ltd | Compound |
GB0325745D0 (en) * | 2003-11-05 | 2003-12-10 | Astrazeneca Ab | Chemical compounds |
AP2006003633A0 (en) * | 2003-12-19 | 2006-06-30 | Pfizer | Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-BETA-hydroxysteroid dehydrogenase type 1 (11-BETA-HSD-1) for the treatment of diabetes and obesity |
US7365075B2 (en) | 2003-12-22 | 2008-04-29 | Amgen Inc. | Aryl sulfonamide compounds and uses related thereto |
JP2007519726A (ja) | 2004-01-26 | 2007-07-19 | メルク エンド カムパニー インコーポレーテッド | 11−ベータ−ヒドロキシステロイドデヒドロゲナーゼ1型の阻害剤の、新規結晶形態 |
US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
JP2007261945A (ja) * | 2004-04-07 | 2007-10-11 | Taisho Pharmaceut Co Ltd | チアゾール誘導体 |
WO2005110980A2 (en) * | 2004-04-14 | 2005-11-24 | Amgen, Inc. | Aryl sulfones and uses related thereto |
GB0408771D0 (en) * | 2004-04-20 | 2004-05-26 | Sterix Ltd | Compound |
ES2390057T3 (es) | 2004-04-20 | 2012-11-06 | Amgen Inc. | Arilsulfonilamidas y usos como hidroxiesteroide deshidrogenasa |
CN101001836B (zh) | 2004-05-07 | 2010-12-22 | 詹森药业有限公司 | 作为11-β羟基类固醇脱氢酶抑制剂的吡咯烷-2-酮和哌啶-2-酮衍生物 |
US20070281938A1 (en) | 2004-05-24 | 2007-12-06 | Amgen Inc. | Inhibitors of 11-Beta-Hydroxy Steroid Dehydrogenase Type 1 |
US8686011B2 (en) | 2004-05-24 | 2014-04-01 | Amgen Inc. | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 |
PT1763517E (pt) * | 2004-06-28 | 2011-07-01 | Hoffmann La Roche | Derivados de pirimidina como inibidores 11beta-hsd1 |
AU2005268899B2 (en) * | 2004-08-05 | 2009-09-24 | F. Hoffmann-La Roche Ag | Substituted N-acyl-2-aminothiazoles |
DE602005017159D1 (de) | 2004-08-30 | 2009-11-26 | Janssen Pharmaceutica Nv | Oxysteroid-dehydrogenase-inhibitoren |
CN101039908B (zh) | 2004-08-30 | 2010-06-23 | 詹森药业有限公司 | 作为11-β羟甾类脱氢酶抑制剂的三环内酰胺衍生物 |
WO2006024627A2 (en) | 2004-08-30 | 2006-03-09 | Janssen Pharmaceutica N.V. | N-2 adamantanyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
PT1797042E (pt) * | 2004-09-29 | 2009-02-12 | Hoffmann La Roche | Derivados de indozolona como inibidores de 11b-hsd1 |
JP5414990B2 (ja) * | 2004-10-04 | 2014-02-12 | エフ.ホフマン−ラ ロシュ アーゲー | 糖尿病のための11−β阻害剤としてのアルキルピリジン |
KR101325519B1 (ko) * | 2004-10-14 | 2013-11-08 | 애보트 게엠베하 운트 콤파니 카게 | 도파민 d3 수용체의 조절에 반응하는 장애를 치료하기에적합한 아릴설포닐메틸 또는 아릴설폰아미드 치환된 방향족화합물 |
EP1809619A1 (en) | 2004-10-21 | 2007-07-25 | Transtech Pharma, Inc. | Bissulfonamide compounds as agonists of galr1, compositions, and methods of use |
EP1659113A1 (en) * | 2004-11-08 | 2006-05-24 | Evotec AG | Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1) |
EP1666467A1 (en) * | 2004-11-08 | 2006-06-07 | Evotec AG | 11Beta-HSD1 Inhibitors |
WO2006051662A1 (ja) * | 2004-11-09 | 2006-05-18 | Taisho Pharmaceutical Co., Ltd. | チアゾール誘導体 |
WO2006059507A1 (ja) * | 2004-11-30 | 2006-06-08 | Sankyo Company, Limited | 11β-HSD1アンチセンス化合物 |
EP1888544A2 (en) * | 2004-12-17 | 2008-02-20 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
GB0506133D0 (en) * | 2005-03-24 | 2005-05-04 | Sterix Ltd | Compound |
EP1866298A2 (en) | 2005-03-31 | 2007-12-19 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
ATE519744T1 (de) | 2005-04-05 | 2011-08-15 | Hoffmann La Roche | 1h-pyrazol-4-carbonsäure-amide, deren herstellung und verwendung als 11-beta-hydroxysteroid- dehydrogenase-hemmer |
RU2417985C2 (ru) | 2005-05-30 | 2011-05-10 | Баниу Фармасьютикал Ко., Лтд. | Новые производные пиперидина |
WO2006134481A1 (en) * | 2005-06-16 | 2006-12-21 | Pfizer Inc. | Inhibitors of 11-beta hydroxysteroid dehydrogenase type 1 |
MX2007016319A (es) * | 2005-06-16 | 2008-03-10 | Pfizer | Derivados de n-(piridin-2-il)-sulfonamida. |
US20100216758A1 (en) | 2005-08-10 | 2010-08-26 | Makoto Ando | Pyridone Compounds |
JPWO2007024004A1 (ja) | 2005-08-24 | 2009-03-05 | 萬有製薬株式会社 | フェニルピリドン誘導体 |
US7622492B2 (en) | 2005-08-31 | 2009-11-24 | Hoffmann-La Roche Inc. | Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase |
EP1939194A4 (en) | 2005-09-07 | 2010-12-08 | Banyu Pharma Co Ltd | AROMATIC SUBSTITUTED BICYLIC PYRIDONE DERIVATIVE |
EP1940842B1 (en) | 2005-09-29 | 2012-05-30 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
JP2007099659A (ja) * | 2005-10-03 | 2007-04-19 | Toray Fine Chemicals Co Ltd | ピペラジンカルボン酸エステルの製造法 |
JP2009511599A (ja) * | 2005-10-12 | 2009-03-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | 電位依存性イオンチャネルの調整剤としてのビフェニル誘導体 |
JP2009512715A (ja) | 2005-10-21 | 2009-03-26 | ノバルティス アクチエンゲゼルシャフト | レニン阻害剤と抗異脂肪血症剤および/または抗肥満症剤の組み合わせ |
CA2627139A1 (en) | 2005-10-27 | 2007-05-03 | Banyu Pharmaceutical Co., Ltd. | Novel benzoxathiin derivative |
EP1953165B1 (en) | 2005-11-10 | 2012-02-01 | Msd K.K. | Aza-substituted spiro derivative |
US20070110802A1 (en) * | 2005-11-15 | 2007-05-17 | Janan Jona | Wet granulation process |
EP1951696A2 (en) | 2005-11-22 | 2008-08-06 | Amgen Inc. | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
KR20080081178A (ko) | 2005-12-21 | 2008-09-08 | 버텍스 파마슈티칼스 인코포레이티드 | 이온 채널 조절인자로서의 헤테로사이클릭 유도체 |
WO2007076875A2 (en) * | 2006-01-06 | 2007-07-12 | Aarhus Universitet | Compounds acting on the serotonin transporter |
WO2007082808A2 (en) | 2006-01-18 | 2007-07-26 | F. Hoffmann-La Roche Ag | Thiazoles as 11 beta-hsd1 inhibitors |
DK2049475T3 (da) * | 2006-04-24 | 2012-03-05 | Lilly Co Eli | Cyclohexyl-substituerede pyrrolidinoner som inhibitorer af 11-beta-hydroxysteroid dehydrogenase1 |
AU2007244960B2 (en) * | 2006-04-24 | 2012-03-01 | Eli Lilly And Company | Substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
CN101096363B (zh) * | 2006-06-27 | 2011-05-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 2,4,5-三取代噻唑类化合物、其制备方法、药物组合物及其制药用途 |
RU2009108280A (ru) | 2006-08-08 | 2010-09-20 | Санофи-Авентис (Fr) | Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение |
EP2083831B1 (en) | 2006-09-22 | 2013-12-25 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
CA2664358A1 (en) | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | Diarylketimine derivative |
DE102007005045B4 (de) | 2007-01-26 | 2008-12-18 | Sanofi-Aventis | Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
CN101668524B (zh) * | 2007-02-12 | 2012-10-24 | 阿斯利康(瑞典)有限公司 | 作为11-β-HSD1抑制剂的吡唑衍生物 |
WO2008101885A1 (en) | 2007-02-23 | 2008-08-28 | High Point Pharmaceuticals, Llc | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase |
EA016951B1 (ru) | 2007-02-23 | 2012-08-30 | ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | N-АДАМАНТИЛБЕНЗАМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ 11-β-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗЫ |
WO2008101886A1 (en) | 2007-02-23 | 2008-08-28 | High Point Pharmaceuticals, Llc | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase |
ATE461177T1 (de) | 2007-03-23 | 2010-04-15 | Icagen Inc | Ionenkanal-hemmer |
EP2145884B1 (en) | 2007-04-02 | 2014-08-06 | Msd K.K. | Indoledione derivative |
ES2399912T3 (es) * | 2007-04-11 | 2013-04-04 | High Point Pharmaceuticals, Llc | Nuevos compuestos |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
EA020466B1 (ru) | 2007-06-04 | 2014-11-28 | Синерджи Фармасьютикалз Инк. | Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний |
JP5223864B2 (ja) | 2007-06-27 | 2013-06-26 | 大正製薬株式会社 | 11β−HSD1阻害活性を有する化合物 |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
WO2009110510A1 (ja) | 2008-03-06 | 2009-09-11 | 萬有製薬株式会社 | アルキルアミノピリジン誘導体 |
JPWO2009119726A1 (ja) | 2008-03-28 | 2011-07-28 | Msd株式会社 | メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体 |
CA2726917C (en) | 2008-06-04 | 2018-06-26 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
AU2009261248A1 (en) | 2008-06-19 | 2009-12-23 | Banyu Pharmaceutical Co., Ltd. | Spirodiamine-diarylketoxime derivative |
TW201014822A (en) | 2008-07-09 | 2010-04-16 | Sanofi Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
CA2730603C (en) | 2008-07-16 | 2019-09-24 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
JPWO2010013595A1 (ja) | 2008-07-30 | 2012-01-12 | Msd株式会社 | 5員−5員又は5員−6員縮環シクロアルキルアミン誘導体 |
CN102264228A (zh) | 2008-10-22 | 2011-11-30 | 默沙东公司 | 用于抗糖尿病药的新的环状苯并咪唑衍生物 |
JP5635991B2 (ja) | 2008-10-30 | 2014-12-03 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | イソニコチンアミドオレキシン受容体アンタゴニスト |
US8329914B2 (en) | 2008-10-31 | 2012-12-11 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
KR200452117Y1 (ko) * | 2008-11-10 | 2011-02-08 | 대성공업주식회사 | 휠체어용 브레이크 와이어 케이블 지지 브래킷 |
US8927549B2 (en) * | 2008-11-21 | 2015-01-06 | High Point Pharmaceuticals, Llc | Adamantyl benzamide derivatives |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
ES2350077B1 (es) | 2009-06-04 | 2011-11-04 | Laboratorios Salvat, S.A. | Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1. |
JP2013503135A (ja) | 2009-08-26 | 2013-01-31 | サノフイ | 新規な結晶性複素芳香族フルオログリコシド水和物、その化合物を含んでなる医薬及びその使用 |
WO2011106273A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
WO2012015715A1 (en) * | 2010-07-27 | 2012-02-02 | High Point Pharmaceuticals, Llc | Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta hsd1 modulators |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
CA2826649C (en) | 2011-02-25 | 2016-07-26 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
WO2012118972A2 (en) | 2011-03-01 | 2012-09-07 | Synegy Pharmaceuticals Inc. | Process of preparing guanylate cyclase c agonists |
US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683701B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
CN103204824B (zh) * | 2012-01-12 | 2015-04-08 | 清华大学深圳研究生院 | 2-氨基噻唑-4-酰胺类衍生物及其制备方法与应用 |
US20140045746A1 (en) | 2012-08-02 | 2014-02-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
BR112015019836A2 (pt) | 2013-02-22 | 2017-07-18 | Merck Sharp & Dohme | composto, composição farmacêutica, e, uso de um composto |
US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
EP2970384A1 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
TW201512171A (zh) | 2013-04-19 | 2015-04-01 | Pfizer Ltd | 化學化合物 |
CN113388007A (zh) | 2013-06-05 | 2021-09-14 | 博士医疗爱尔兰有限公司 | 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法 |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
EP3186242B1 (en) | 2014-08-29 | 2021-10-06 | Tes Pharma S.r.l. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
CN105001152A (zh) * | 2015-07-19 | 2015-10-28 | 佛山市赛维斯医药科技有限公司 | 一类二甲胺基二吡啶叔醇结构的11β-HSD1抑制剂及其用途 |
CN105017135A (zh) * | 2015-07-19 | 2015-11-04 | 佛山市赛维斯医药科技有限公司 | 一类二吡啶叔醇结构的11β-HSD1抑制剂、制备方法及其用途 |
EP3235813A1 (en) | 2016-04-19 | 2017-10-25 | Cidqo 2012, S.L. | Aza-tetra-cyclo derivatives |
EP3526199B1 (en) | 2016-10-14 | 2022-04-13 | Tes Pharma S.r.l. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
CN107663204A (zh) * | 2016-10-19 | 2018-02-06 | 首都医科大学附属北京世纪坛医院 | 一种化合物的抗结核应用 |
US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
EP3558298A4 (en) | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | ANTIDIABETIC SPIROCHROMAN COMPOUNDS |
WO2019106156A1 (en) * | 2017-11-30 | 2019-06-06 | Step Pharma S.A.S. | Compounds |
EP3717465A1 (en) | 2017-11-30 | 2020-10-07 | Step Pharma S.A.S. | Compounds |
US11066417B2 (en) | 2018-02-15 | 2021-07-20 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators |
CN108358869B (zh) * | 2018-03-27 | 2019-09-10 | 河北师范大学 | 一种n-苯并噻唑基苯磺酰胺类衍生物、制备方法及用途 |
CN108659219B (zh) * | 2018-06-08 | 2021-02-09 | 扬州大学 | 一种聚苯胺的制备方法 |
CN113302189A (zh) | 2018-11-20 | 2021-08-24 | Tes制药有限责任公司 | α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂 |
CN109748831A (zh) * | 2018-12-17 | 2019-05-14 | 南通正达农化有限公司 | 一种三氟甲磺酸三氟乙酯的制备方法 |
EP3924058A1 (en) | 2019-02-13 | 2021-12-22 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
EP4010314B1 (en) | 2019-08-08 | 2024-02-28 | Merck Sharp & Dohme LLC | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
TW202120517A (zh) | 2019-08-14 | 2021-06-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
TW202115092A (zh) | 2019-08-14 | 2021-04-16 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
US11873300B2 (en) | 2019-08-14 | 2024-01-16 | Vertex Pharmaceuticals Incorporated | Crystalline forms of CFTR modulators |
CN111620837B (zh) * | 2020-06-29 | 2022-02-15 | 郑州大学 | 香柏酮噻唑酰胺类化合物、及其制备方法和应用 |
JP7443625B2 (ja) | 2020-08-18 | 2024-03-05 | メルク・シャープ・アンド・ドーム・エルエルシー | ビシクロヘプタンピロリジンオレキシン受容体アゴニスト |
WO2022076629A1 (en) * | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
CN112451514A (zh) * | 2020-11-26 | 2021-03-09 | 江西农业大学 | 二氢杨梅素纳米硒及其制备方法和应用 |
CN113461635A (zh) * | 2021-07-07 | 2021-10-01 | 上海毕得医药科技股份有限公司 | 4-(2-氯乙基)噻唑-2-羧酸乙酯及其制备方法和应用 |
IL310864A (en) * | 2021-08-20 | 2024-04-01 | Enanta Pharm Inc | 17-beta-hydroxysteroid dehydrogenase type 17 inhibitors and methods of using them |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB517272A (en) * | 1938-06-03 | 1940-01-25 | May & Baker Ltd | The preparation of new therapeutically useful heterocyclic compounds |
GB620654A (en) * | 1939-10-03 | 1949-03-29 | Chinoin Gyogyszer Es Vegyeszet | A process for the preparation of sulphonamide derivatives of 2-amino-thiazole |
US2611770A (en) * | 1949-04-16 | 1952-09-23 | American Cyanamid Co | N-(2-thiazolyl)-2-hydroxypyridine-5-sulfonamides |
GB822947A (en) | 1957-01-25 | 1959-11-04 | Smith & Nephew | Improvements in and relating to sulphonamides |
DE1620508A1 (de) * | 1965-07-23 | 1969-09-18 | Thomae Gmbh Dr K | Verfahren zur Herstellung neuer 4,5,6,7-Tetrahydrothiazolo-[5,4-c]-pyridine |
CA1088049A (en) * | 1975-06-03 | 1980-10-21 | Takashi Masugi | 3-substituted-7-substituted alkanamido-3-cephem-4- carboxylic acid compounds and processes for preparation thereof |
FR2384498A1 (fr) * | 1975-11-26 | 1978-10-20 | Parcor | Nouveaux derives sulfonylamino thiazoliques et leurs applications en medecine humaine et veterinaire |
EP0246749A3 (en) * | 1986-05-17 | 1988-08-31 | AgrEvo UK Limited | Triazole herbicides |
US5962490A (en) * | 1987-09-25 | 1999-10-05 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
US5591761A (en) | 1993-05-20 | 1997-01-07 | Texas Biotechnology Corporation | Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
US5594021A (en) | 1993-05-20 | 1997-01-14 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin |
JPH021483A (ja) | 1988-03-10 | 1990-01-05 | Nippon Tokushu Noyaku Seizo Kk | 農業用殺菌剤 |
JPH078863B2 (ja) * | 1989-09-21 | 1995-02-01 | 久光製薬株式会社 | 新規なジフェニルチアゾール誘導体 |
EP0532239B1 (en) | 1991-09-10 | 1995-12-13 | Zeneca Limited | Benzenesulphonamide derivatives as 5-lipoxygenase inhibitors |
JPH0670024B2 (ja) | 1993-04-13 | 1994-09-07 | 塩野義製薬株式会社 | グルタコン酸エステル誘導体の製法 |
US6030991A (en) | 1993-05-20 | 2000-02-29 | Texas Biotechnology Corp. | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
JPH07149745A (ja) * | 1993-11-30 | 1995-06-13 | Hisamitsu Pharmaceut Co Inc | 新規な2−アミノチアゾール誘導体 |
JPH07149746A (ja) * | 1993-11-30 | 1995-06-13 | Hisamitsu Pharmaceut Co Inc | 新規な2−置換アミノチアゾール誘導体 |
JPH07309757A (ja) * | 1994-05-18 | 1995-11-28 | Asahi Chem Ind Co Ltd | βアミロイド蛋白神経細胞毒性低減剤 |
KR100422162B1 (ko) | 1994-08-09 | 2004-07-07 | 메타볼릭 신드롬 아이 지비지 에이비 | 케토코나졸을포함하는당뇨병타입ii의치료용약제 |
CA2206315A1 (en) * | 1994-11-29 | 1996-06-06 | Hisamitsu Pharmaceutical Co., Inc. | Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof |
SE505391C2 (sv) | 1995-05-30 | 1997-08-18 | Cortendo Ab | Användning av kortisol-agonister för framställning av ett system för diagnostisering av det metabola syndromet |
GB9512697D0 (en) | 1995-06-22 | 1995-08-23 | Zeneca Ltd | Heterocyclic compounds |
GB9517622D0 (en) | 1995-08-29 | 1995-11-01 | Univ Edinburgh | Regulation of intracellular glucocorticoid concentrations |
WO1997047299A1 (en) * | 1996-06-12 | 1997-12-18 | 3-Dimensional Pharmaceuticals, Inc. | Amidino and guanidino heterocyclic protease inhibitors |
US5877193A (en) | 1996-07-19 | 1999-03-02 | Hoffmann-La Roche Inc. | Use of N-(4-aryl-thiazol-2-yl)-sulfonamides |
ATE229949T1 (de) | 1996-10-16 | 2003-01-15 | American Cyanamid Co | Herstellung und verwendung von ortho-sulfonamido- heteroarylhydroxamsäuren als matrix- metalloproteinase und tace inhibitoren |
DZ2376A1 (fr) | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
SE9700642D0 (sv) | 1997-02-24 | 1997-02-24 | Kronvall Stefan Med Ab | Medel och sätt för förebyggande och behandling av det metabola syndromet |
US5783597A (en) | 1997-03-04 | 1998-07-21 | Ortho Pharmaceutical Corporation | 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use |
ATE296811T1 (de) | 1997-07-11 | 2005-06-15 | Smithkline Beecham Plc | Sulfonamid-derivate als 5-ht6 receptor antagonisten und verfahren zu ihrer herstellung |
GB9725141D0 (en) * | 1997-11-27 | 1998-01-28 | Pharmacia & Upjohn Spa | Benzenesulfonamide compounds |
JP2002518380A (ja) | 1998-06-18 | 2002-06-25 | ブリストル−マイヤーズ スクイブ カンパニー | サイクリン依存キナーゼの炭素置換アミノチアゾール抑制剤 |
ATE309206T1 (de) | 1998-07-08 | 2005-11-15 | Sanofi Aventis Deutschland | Schwefel-substituierte sulfonylaminocarbonsäure n-arylamide, ihre herstellung, ihre anwendung und diese enthaltende pharmazeutische zusammensetzungen |
GB9915625D0 (en) | 1999-07-02 | 1999-09-01 | Cortendo Ab | Method |
GB0001449D0 (en) | 2000-01-21 | 2000-03-08 | Cortendo Ab | Compositions |
IT1317735B1 (it) | 2000-01-26 | 2003-07-15 | Nicox Sa | Sali di agenti antimicrobici. |
SE0001899D0 (sv) | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
WO2002028353A2 (en) | 2000-10-05 | 2002-04-11 | Smithkline Beecham Corporation | Phosphate transport inhibitors |
GB0118300D0 (en) | 2001-07-26 | 2001-09-19 | Cortendo Ab | Formulations |
CA2466490C (en) | 2001-11-22 | 2009-12-29 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
US20030130279A1 (en) | 2001-11-22 | 2003-07-10 | Guido Kurz | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
US7074788B2 (en) | 2001-11-22 | 2006-07-11 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
EA200400707A1 (ru) * | 2001-11-22 | 2004-10-28 | Биовитрум Аб | Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1 |
-
2000
- 2000-05-22 SE SE0001899A patent/SE0001899D0/xx unknown
-
2001
- 2001-05-18 PE PE2001000450A patent/PE20020100A1/es not_active Application Discontinuation
- 2001-05-22 AR ARP010102421A patent/AR033534A1/es not_active Application Discontinuation
- 2001-05-22 DE DE60143293T patent/DE60143293D1/de not_active Expired - Lifetime
- 2001-05-22 JP JP2001586282A patent/JP2003534339A/ja not_active Abandoned
- 2001-05-22 ES ES01937063T patent/ES2333846T3/es not_active Expired - Lifetime
- 2001-05-22 EP EP01938885A patent/EP1283833A1/en not_active Withdrawn
- 2001-05-22 NZ NZ522506A patent/NZ522506A/en unknown
- 2001-05-22 WO PCT/SE2001/001154 patent/WO2001090093A1/en active Application Filing
- 2001-05-22 MX MXPA02011632A patent/MXPA02011632A/es active IP Right Grant
- 2001-05-22 CA CA002408783A patent/CA2408783A1/en not_active Abandoned
- 2001-05-22 JP JP2001586280A patent/JP2003534338A/ja not_active Abandoned
- 2001-05-22 AT AT01937063T patent/ATE443055T1/de not_active IP Right Cessation
- 2001-05-22 AU AU2001262830A patent/AU2001262830A1/en not_active Abandoned
- 2001-05-22 IL IL15266901A patent/IL152669A0/xx unknown
- 2001-05-22 US US10/296,553 patent/US7618961B2/en not_active Expired - Fee Related
- 2001-05-22 CN CNB018099661A patent/CN1188403C/zh not_active Expired - Fee Related
- 2001-05-22 PL PL36013701A patent/PL360137A1/xx not_active IP Right Cessation
- 2001-05-22 KR KR1020027015743A patent/KR20030016272A/ko not_active Application Discontinuation
- 2001-05-22 WO PCT/SE2001/001158 patent/WO2001090092A1/en active IP Right Grant
- 2001-05-22 IL IL15275301A patent/IL152753A0/xx unknown
- 2001-05-22 IL IL15279001A patent/IL152790A0/xx unknown
- 2001-05-22 HU HU0302435A patent/HUP0302435A3/hu unknown
- 2001-05-22 CA CA2409697A patent/CA2409697C/en not_active Expired - Fee Related
- 2001-05-22 EP EP01934781A patent/EP1283831A1/en not_active Withdrawn
- 2001-05-22 AU AU6283101A patent/AU6283101A/xx active Pending
- 2001-05-22 US US10/296,552 patent/US7132436B2/en not_active Expired - Fee Related
- 2001-05-22 KR KR1020027015741A patent/KR20030011341A/ko not_active Application Discontinuation
- 2001-05-22 KR KR1020027015742A patent/KR20030016271A/ko not_active Application Discontinuation
- 2001-05-22 AT AT01934782T patent/ATE485283T1/de not_active IP Right Cessation
- 2001-05-22 AU AU2001262831A patent/AU2001262831B9/en not_active Ceased
- 2001-05-22 KR KR1020027015703A patent/KR20030016269A/ko not_active Application Discontinuation
- 2001-05-22 CA CA002408144A patent/CA2408144C/en not_active Expired - Fee Related
- 2001-05-22 CN CN01811609A patent/CN1437588A/zh active Pending
- 2001-05-22 NZ NZ522507A patent/NZ522507A/en unknown
- 2001-05-22 DE DE60139931T patent/DE60139931D1/de not_active Expired - Lifetime
- 2001-05-22 NZ NZ522591A patent/NZ522591A/en unknown
- 2001-05-22 AU AU6093201A patent/AU6093201A/xx not_active Withdrawn
- 2001-05-22 JP JP2001586278A patent/JP2003534336A/ja not_active Abandoned
- 2001-05-22 EP EP01934782A patent/EP1283832B1/en not_active Expired - Lifetime
- 2001-05-22 WO PCT/SE2001/001156 patent/WO2001090091A1/en active IP Right Grant
- 2001-05-22 AU AU6445601A patent/AU6445601A/xx not_active Withdrawn
- 2001-05-22 BR BR0111099-3A patent/BR0111099A/pt not_active IP Right Cessation
- 2001-05-22 WO PCT/SE2001/001157 patent/WO2001090094A1/en active IP Right Grant
- 2001-05-22 WO PCT/SE2001/001155 patent/WO2001090090A1/en active IP Right Grant
- 2001-05-22 EP EP01937063A patent/EP1283834B1/en not_active Expired - Lifetime
- 2001-05-22 DE DE1283831T patent/DE1283831T1/de active Pending
- 2001-05-22 JP JP2001586279A patent/JP2003534337A/ja not_active Abandoned
- 2001-05-22 US US10/296,132 patent/US7030135B2/en not_active Expired - Fee Related
- 2001-05-22 EA EA200201271A patent/EA005274B1/ru not_active IP Right Cessation
- 2001-05-22 AU AU6093101A patent/AU6093101A/xx not_active Withdrawn
- 2001-05-22 US US10/276,954 patent/US7125900B2/en not_active Expired - Fee Related
- 2001-05-22 CN CN01809979A patent/CN1430614A/zh active Pending
- 2001-05-22 CA CA002408142A patent/CA2408142C/en not_active Expired - Fee Related
- 2001-05-22 IL IL15267001A patent/IL152670A0/xx unknown
- 2001-05-22 CN CNB018116787A patent/CN1249039C/zh not_active Expired - Fee Related
- 2001-05-22 NZ NZ522538A patent/NZ522538A/en unknown
-
2002
- 2002-11-18 ZA ZA200209360A patent/ZA200209360B/en unknown
- 2002-11-18 ZA ZA200209362A patent/ZA200209362B/en unknown
- 2002-11-18 ZA ZA200209359A patent/ZA200209359B/en unknown
- 2002-11-18 ZA ZA200209364A patent/ZA200209364B/en unknown
- 2002-11-21 NO NO20025588A patent/NO20025588L/no not_active Application Discontinuation
- 2002-11-21 NO NO20025585A patent/NO323831B1/no not_active IP Right Cessation
- 2002-11-21 NO NO20025586A patent/NO323832B1/no not_active IP Right Cessation
- 2002-11-21 NO NO20025587A patent/NO323779B1/no not_active IP Right Cessation
-
2003
- 2003-12-19 HK HK03109254A patent/HK1056878A1/xx not_active IP Right Cessation
-
2005
- 2005-11-30 US US11/289,634 patent/US20060160797A1/en not_active Abandoned
-
2006
- 2006-08-29 US US11/511,224 patent/US20060287374A1/en not_active Abandoned
-
2009
- 2009-11-16 US US12/619,216 patent/US20100113435A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1056878A1 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1. | |
IL160630A0 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
IL160648A0 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
AU2001244399A1 (en) | Gamma-secretase inhibitors | |
AU2001258771A1 (en) | -secretase inhibitors | |
PL376301A1 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2 | |
AU4882101A (en) | Mmp-12 inhibitors | |
MXPA03000694A (es) | Nuevo uso de los inhibidores de lipasa. | |
AU2001253255A1 (en) | Compositions and methods for inhibiting gene expression | |
AU2001285750A1 (en) | Urokinase inhibitors | |
AU2002225894A1 (en) | Methods and compositions for the control of coccidiosis | |
AU2001255090A1 (en) | Cdk inhibitors having 3-hydroxychromen-4-one structure | |
ZA200502909B (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2. | |
AU2002224550A1 (en) | Corrosion inhibitors | |
AUPQ629000A0 (en) | Inhibition of fungi | |
GB0030284D0 (en) | Enzyme inhibitors | |
AU2001264522A1 (en) | Methods and compositions for the prevention of myopia | |
AU2001251631A1 (en) | Hydrazide and alkoxyamide angiogenesis inhibitors | |
AU7887100A (en) | Corrosion inhibitor | |
AU2001250996A1 (en) | Compositions and methods for the deoxidation of steel | |
AU1548801A (en) | Melanogenesis inhibitor | |
AU2001273847A1 (en) | Polydesoxyribonucleotides for inhibiting the expression of the icam-1-gene | |
ZA200210029B (en) | Compositions and methods for the modification of gene expression. | |
AU2001240374A1 (en) | Inhibition of fungi | |
ZA200003399B (en) | Inhibitors. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20090522 |